Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
Allogeneic bone marrow transplantation is an effective treatment of leukemia. Intensive chemo- and radiotherapy used for conditioning and T-cells of the graft contribute to the control of leukemia. Animal experiments indicate that transfusion of lymphocytes from the marrow donor convert into complete chimerism without producing graft-versus-host disease, if delayed for two months or more. Transfusion of donor leukocytes (DLT) after marrow transplantation has induced lasting remissions in the majority of patients with chronic myelogenous leukemia (CML) in hematological or cytogenetic relapse, some patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), transformed phase CML and multiple myeloma (MMY). The mechanism of the graft-versus-leukemia reaction is discussed.
GSF-National Research Center for Environment and Health, Klinikum Grosshadern, University Munich, Germany. kolb@med3.med.uni-muenchen.de
H J
HJ
Kolb
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002678:Chimera; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D018572:Disease-Free Survival; D004285:Dogs; D005260:Female; D020350:Graft vs Tumor Effect; D006131:Growth Inhibitors / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D007942:Leukemia, Experimental / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D017708:Leukocyte Transfusion; D015993:Life Tables; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D019172:Transplantation Conditioning; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016207:Cytokines; D006131:Growth Inhibitors; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D016898:Interferon-alpha